The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.
Stephen John Clarke, Matthew E Burge, Kynan Feeney, Kristian Jones, Peter Gibbs, Mark P Molloy, Gavin M Marx, Timothy Jay Price, William Reece, Eva Segelov, Niall C Tebbutt
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
719 Background: Bevacizumab (BEV) with fluoropyrimidine-containing chemotherapy is well-established for patients (pts) with mCRC. There is a need for reproducible, validated, inexpensive and accessible prognostic markers to aid in treatment selection. Pre-treatment levels of systemic inflammatory markers including the neutrophil to lymphocyte ratio (NLR) have been shown retrospectively to be prognostic in many tumors. This study aimed to prospectively evaluate the relationship between NLR and treatment outcomes in previously untreated mCRC pts receiving BEV-based therapy. Methods: ASCENT (NCT01588990) is an open-label, single arm, phase-IV, multi-center study. Pts received 1st-line BEV+XELO..View full abstract